

LJMU Research Online

Davies, MJ, Birkett, JW, Kotwa, M, Tomlinson, L and Woldtinsae, R

The impact of cigarette/e-cigarette vapour on simulated pulmonary surfactant monolayers under physiologically relevant conditions

https://researchonline.ljmu.ac.uk/id/eprint/5333/

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Davies, MJ, Birkett, JW, Kotwa, M, Tomlinson, L and Woldtinsae, R (2017) The impact of cigarette/e-cigarette vapour on simulated pulmonary surfactant monolayers under physiologically relevant conditions. Surface and Interface Analysis. ISSN 1096-9918

LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

http://researchonline.ljmu.ac.uk/

1	The Impact of Cigarette / e-Cigarette Vapour on
2	Simulated Pulmonary Surfactant Monolayers under Physiologically Relevant Conditions
3	
4	Michael J. Davies ^{a, *} , Jason W. Birkett ^a , Mateusz Kotwa ^a , Lauren Tomlinson ^a & Rezene Woldetinsae ^a
5	^a The School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, UK.
6	

7 Abstract

8 Deviation in pulmonary surfactant structure-function activity can impair airway patency and lead to respiratory 9 disorders. This novel study aims to evaluate the influence cigarette / e-cigarette vapour has on model 10 surfactant films located within a simulated pulmonary environment using a lung biosimulator. 11 Chromatographic analysis confirmed that nicotine levels were consistent with the sampling regimen 12 employed. On exposure to smoke vapour, Langmuir isotherms exhibited condensed character and a 13 significant reduction in maximum surface pressure was noted in all cases. Langmuir isocycles, reflective of the 14 human breathing cycle, demonstrated condensed character on smoke vapour delivery. A reduction in the 15 maximum surface pressure was clear only in the case of cigarette vapour application. The components of 16 cigarette vapour can cause oxidative damage to pulmonary surfactant and impair recycling. Neutral nicotine 17 molecules can weaken the structure of the monolayer and cause destabilisation. A protective effect was 18 evident in the case of repeated surfactant compression - relaxation cycles (i.e. the ability to reduce the surface 19 tension term was impaired less), demonstrating a likely innate biological defensive mechanism of the lung. E-20 cigarette vapour appeared to have a reduced impact on surfactant performance, which may hold value in 21 harm reduction over the longer term.

22

23 Key words

Langmuir monolayers, pulmonary surfactant, lung biosimulator, smoking, cigarettes, e-cigarettes, gas
 chromatography.

- 26
- -
- 27
- 28 Corresponding Author Details:
- 29
- 30 * To whom correspondence should be addressed:
- 31 Tel. (+44) 0151 231 2024
- 32 Email: <u>m.davies1@ljmu.ac.uk</u>
- 33 Fax. (+44) 0151 231 2170
- 34
- 35
- 36
- 37
- 57
- 38

- 39 1. Introduction
- 40

41 The primary function of the lung is to permit gaseous exchange between the body and the 42 atmosphere. The main site for such exchange is the alveolar space, which exhibits a moist and highly 43 vascularised surface of approximately 70m² [1]. The naturally occurring fluid that bathes the 44 alveolar lining is subject to considerable surface tension that can force structural collapse on 45 exhalation [2]. In order to counter this effect, and also minimise the work of breathing, a complex 46 and highly surface active mix called pulmonary surfactant is distributed at the alveolar air-liquid 47 interface [3]. The arrangement results in pulmonary surfactant presenting as the initial contacting 48 surface for aerosolised material. Prime examples of such material include respirable therapeutic 49 formulations [4] and, importantly for work presented herein, environmental toxins such as cigarette 50 / e-cigarette vapour [5 & 6].

51

52 Pulmonary surfactant is synthesised and secreted by alveolar type II cells located in the deep lung. 53 This endogenous substance exists as an insoluble film that coats the alveolar air-liquid interface [7]. As a result of inherent material characteristics, pulmonary surfactant is capable of reducing the 54 55 surface tension term to near zero values [8 & 9], which in turn facilitates alveolar stability [3]. In 56 order to achieve this, a dynamic interplay exists between the phospholipid molecules and surfactant 57 specific proteins within the naturally occurring blend. With regard to the former, dipalmitoylphosphatidylcholine (DPPC) predominates and is principally responsible for the surface 58 59 tension lowering properties of the material [8]. As this amphiphilic molecule undergoes a gel to liquid transition at 41°C, thus the ability to respread across the alveolar air-liquid interface is limited 60 during the breathing cycle [1]. Consequently, additional species are required in order to maintain 61 fluidity and support surfactant respreading. For instance, palmitoyloleoylphosphatidylglycerol 62 (POPG) facilitates effective respreading of pulmonary surfactant following compression [2]. 63 64 Commercially available lung surfactant replacement preparations (e.g. Survanta®) are frequently prescribed for the management of neonatal respiratory distress syndrome [10]. Such products are 65 often supplemented with palmitic acid (PA), which permits comparable in vivo respreading profiles 66 [11]. Thus, throughout this work an appropriate blend of DPPC, POPG and PA is applied to reflect 67 68 the key lipid fractions of pulmonary surfactant located at the alveolar air-liquid interface.

- 70
- 71

A Langmuir trough may be used within the laboratory setting to represent the alveolar air-liquid interface [4, 7 & 12]. Here, amphiphilic molecules arrange themselves as per the *in vivo* scenario with their fatty acyl chains displaced away from the supporting aqueous subphase and the polar head groups in direct contact [1]. Scope exists to control environmental parameters with the option to operate at a temperature of 37°C and conduct investigations at elevated relative humidity, as per the (deep) lung; this arrangement may now be investigated via the lung biosimulator [13].

78 Lateral forces may be applied to simulated pulmonary surfactant monolayers in isolation or indeed 79 succession to achieve expansion / compression cycles reflective of the human breathing pattern 80 [14]. Typical outputs from the approach include Langmuir pressure-area (π -A) isotherms and 81 isocycles, which can be applied to monitor the response of the amphiphilic material when exposed 82 to environmental stressors (i.e. cigarette smoke). For example, in 2003 Bringezu and co-workers 83 applied Langmuir monolayer technology to evaluate the effect of environmental tobacco smoke 84 (ETS) on simulated pulmonary surfactant structure-function activity [11]. The investigation utilised a 85 mixture of DPPC, POPG and PA in the ratio of 69:20:11 to maintain the lipid fraction consistent with 86 clinically used replacement pulmonary surfactant [12]. Here, the surfactant blend was applied to a 87 supporting aqueous subphase that had been previously exposed to ETS. The results from the study 88 suggested that ETS exposure impacts upon monolayer phase behaviour and morphology leading to a higher minimum surface tension (i.e. reduced maximum surface pressure) and impaired lung 89 90 function.

91 Tobacco smoking has now become one of the most pervasive habits in modern day society [1]. 92 Tobacco smoke consists of a range of chemical compounds, including aldehydes, amides, amines, 93 carboxylic acids, ketones, esters, phenols and hydrocarbons. The chemical compounds can be 94 further divided into three classes, tobacco-specific nitrosamines (TSNAs), polyaromatic hydrocarbons 95 (PAHs) and volatile organic compounds (VOCs). Compounds assigned to TSNAs, such as N'-96 nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) comprise of 97 chemicals of known carcinogenic affect, which occur during the manufacturing, fermentation and 98 combustion of tobacco. PAHs, such as naphthalene are located in the particulate composition of 99 tobacco smoke and are produced during the incomplete combustion of the organic material.

- 100
- 101
- 102
- 103

104 In order to minimise exposure to the toxic constituents of tobacco smoke, and hence reduce 105 associated long-term deleterious effects, the consumer now has available a range of potential 106 reduced exposure products (PREPs) to purchase [15]. One of the most recently released PREPs is the 107 e-cigarette, which is becoming increasingly popular [16]. As e-cigarettes imitate traditional 108 cigarettes, they not only deliver nicotine but also simulate the process of smoking to satisfy 109 psychological cravings. However, in contrast to traditional cigarettes, e-cigarettes do not involve 110 tobacco combustion. Here, the consumer inhales a vapour that is produced by heating a solution 111 consisting of processed nicotine extract from tobacco leaves, water, glycerine and / or propylene 112 glycol along with flavourings [17]. Potentially harmful constituents present in e-cigarette vapour 113 include carbonyl compounds, volatile organic compounds, TSNAs and heavy metals [17]. All can 114 have toxic, irritating and / or carcinogenic effect on the human body [18].

115 This novel study aims to monitor the response of simulated pulmonary surfactant monolayers when 116 challenged with cigarette / e-cigarette vapour under physiologically relevant conditions (i.e. 37°C 117 and elevated relative humidity). For the first time we apply a patented technology platform to quantitatively probe the influence of cigarette / e-cigarette vapour on the performance of a mixed 118 119 surfactant film located within an environment reflective of the (deep) lung. This work is of interest 120 because it provides a strategy by which to better understand fundamental interactions taking place 121 at a biological interface that is crucial to sustaining life. The timely work will further current 122 understanding of the health impacts associated with smoking cigarettes / e-cigarettes. Throughout 123 the piece consideration will be given to the reproducibility of nicotine presentation within the 124 sampling routine, the identification of chemical species within aerosolised samples and potential 125 mechanisms of interaction with simulated pulmonary surfactant.

- 126
- 127
- 128
- 129
- 130
- 131
- 132
- ____
- 133
- 134

- 135 **2. Materials and Methods**
- 136

137 2.1 Materials

138

The surfactants DPPC (Avanti Polar Lipids, USA. Lot: 160PC-312), POPG (Avanti Polar Lipids, USA. Lot: 139 140 160-181PG-131) and PA (Sigma-Aldrich, UK. Lot: PO500) were of analytical grade and used as 141 supplied. Chloroform (CHCl₃) (Sigma-Aldrich, UK) of analytical grade (\geq 99.9%) was employed to clean contacting surfaces and as the spreading solvent. Methanol (HPLC Grade, Sigma-Aldrich, 142 143 34860, Lot: STBF7002V) was employed as the solvent during smoke analysis via gas chromatography. Ultrapure water (Purite, UK), demonstrating a resistivity of $18.M\Omega$ cm, was used both during cleaning 144 145 procedures and as the Langmuir monolayer aqueous subphase. Marlboro Gold cigarettes along with 146 Blu Classic (first generation) and Eleaf iStick 50W, with Eleaf GS Air Tank atomiser (3rd generation) e-147 cigarettes were purchased through a retail sources. The strength of the e-cigarette refills was 148 represented by the amount of nicotine (i.e. mg) per 1ml of the liquid solution. The cartridges used 149 with the first generation device contained 18mg of nicotine per unit. The batteries of each device 150 were fully charged before each test to facilitate reproducible data collection.

151

152 2.2 Methods

153

155

154 2.2.1 Langmuir Monolayer Preparation

156 Surfactant monolayers were produced using a Langmuir trough (Model 102M, Nima Technology, 157 UK). Surfactant free tissues (Kimtech Science, Kimberley-Clark Professional, 75512, UK) were soaked 158 in chloroform and used to clean all contacting glassware and surfaces. Background tests to monitor 159 surface pressure in the absence of surfactant material were performed to ensure trough cleanliness, 160 which was accepted at surface pressures of 0.4mN/m or less on complete barrier compression. A spreading solution composed of DPPC, POPG and PA in the ratio 69:20:11 was produced to reflect 161 162 appropriate lipid fractions at the alveolar air-lipid interface by dissolving the surfactant material in chloroform to a concentration of 1 mg/ml. In total, 10µl of this solution was delivered to the surface 163 164 of the ultrapure water subphase (50ml) at pH 7 by dropwise addition using a Hamilton microsyringe. The volume of 10µl was chosen so as to achieve a steady transition from the gaseous phase through 165 166 to condensed phases on barrier compression and prevent saturation of the π -A isotherms / isocycles 167 at the solid phase point.

169 A period of 10 minutes was allowed to allow chloroform evaporation and surfactant spreading over 170 the 70cm² area. The polytetrafluoroethylene trough barriers were programmed to move to the 171 centre of the trough at a rate of $25 \text{ cm}^2/\text{min}$. Plots of surface pressure vs. percentage trough area for 172 the surfactant system at 37°C and elevated humidity (e.g. 80% RH) were collected using a Wilhelmy plate, formed from Whatman 44 filter paper, at the centre of the compartment. 173


174

2.2.2 Cigarette / e-cigarette Vapour Generation 175

176

The vapour collection regimen involved taking 2 puffs from the cigarettes / e-cigarettes of 50ml total 177 178 volume, over a 4-second puff duration with a 30-second puff interval [19]. The vapour was collected 179 in a 250ml quick fit round bottom flask with 3 outlets. Each cigarette / e-cigarette was connected to 180 a Teflon mouthpiece that was linked to one of the outlets of the round bottom flask using 181 appropriate tubing. The second outlet, of the same size was connected to a 500ml separating funnel 182 and the third outlet was closed with stopper to produce an airtight system. The experimental 183 arrangement for smoke collection is presented in Figure 1.

- 184
- 185



Before each cigarette / e-cigarette was activated, a total of 100ml of water was poured into the separating funnel (i.e. equivalent to 2 puffs). On activation, smoke vapour was collected in the round bottom flask by withdrawing the 50ml of water from the funnel, with the next puff drawn after 30 seconds [19]. Once the second vapour aliquot was obtained, the round bottom flask containing smoke was disconnected from the separating funnel and mouthpiece and the two outlets are closed with stoppers to hold the smoke inside the flask.

203

204 2.2.3 Nicotine Quantification / Smoke Component Determination

205

206 Following the collection of each vapour sample, a total of 2ml of methanol was added to the round 207 bottom flask to solubilise the aerosolised material. Each sample was then filtered with a 0.45µm 208 syringe filter into a glass vial insert. Analysis of nicotine standards and smoke extracts was carried 209 out on an Agilent 7980GC with flame ionisation detection (FID). The analytical column selected was an Agilent J&W DB-1 (30m x 0.250mm x 0.50µm), with a column temperature of 160°C (isocratic). 210 211 The injection type was 1µl split (10:1) (20ml/min 250°C), with nitrogen selected as the carrier gas 212 and the flame ionisation detector temperature programmed at 250°C. Nicotine standards ranging 213 from 0.0078 - 1mg/ml were constructed for nicotine quantification of the vapour extracts. 214 Standards displayed excellent linearity with R² values >0.999. The analysis of 5 replicate smoke 215 samples per cigarette/e cigarette was undertaken.

Evaluation of vapour components was determined using an Agilent 6980GC with 5975MS detection.
The column was an Agilent J&W HP5-MSUI (30m x 0.250mm x 0.25µm) with split (10:1) injection of
1µl. The oven temperature were: 50°C for 5mins, 20°C/min to 255°C held for 1 min, 20°C/min to
300°C held for 5 mins. The mass spectrometer was run in full scan mode from 40-500 AMU. Mass
spectra for recorded peaks were further evaluated using the NIST database (MS search programme
Version 2.0, NIST, MSS Ltd., Manchester, England).


- 222
- 223
- 224
- 225
- 226 227
- 228
- 220
- 229
- 230 231

232 2.2.4 Vapour Addition to Simulated Pulmonary Surfactant Monolayers

233

In order to assess the impact of smoke vapour on simulated pulmonary surfactant monolayers under physiologically relevant conditions, the aerosolised material was transferred from the round bottomed flask to the enclosed lung biosimulator [13], as detailed in Figure 2, using compressed air. Initially, baseline data was collected in the absence of cigarette / e-cigarette vapour. Subsequently, the smoke vapour acquired from either the cigarettes or e-cigarettes was delivered to the test zone. In each case, a period of 10 minutes was allowed for interaction between each species under consideration.





259 To obtain Langmuir isotherms, a single compression was applied towards the centre of the trough at a rate of 25cm²/min. This relatively slow speed was chosen to closely observe the direct impact of 260 261 cigarette / e-cigarette vapour on both the physical state of the simulated pulmonary surfactant plus 262 compression performance. With respect to Langmuir isocycle tests, a total of 14 compression-263 expansion cycles were undertaken at a speed of 100cm²/min. This faster compression speed is more 264 representative of the human breathing cycle and provides an insight into system dynamics on 265 exposure to cigarette / e-cigarette vapour. In this case, the first 4 cycles were used to condition the 266 monolayer such that the equilibrium position was attained. This approach enabled a clearer 267 depiction of the influence of the cigarette / e-cigarette vapour on the simulated pulmonary 268 surfactant monolayer. All Langmuir isotherm tests were repeated five times, whilst Langmuir 269 isocycles were repeated three times and averaged data was used to generate the plots presented 270 herein. On test completion, the remaining vapour was removed from the lung biosimulator by 271 directing through a tube to a nearby fume hood using compressed air.

272

273 2.2.5 The Compressibility of Langmuir Monolayers

274

The compressibility term relating to a Langmuir monolayer refers to the ability of the material to lower the surface tension at the air-liquid interface with minimal change in surface area [20]. Surfactant films should ideally have a low compressibility value such that gaseous exchange can take place over a large surface area [21]. The lower the compressibility term, the more rigid the surfactant film is (i.e. the material is of low elasticity), with the opposite being true [22 & 23]. The parameter is calculated as detailed in Equation 1.

281

282 Compressibility =
$$\frac{1}{A} \times \frac{1}{m}$$

283

Equation 1. *Simulated pulmonary surfactant compressibility determination.*

285

286 Where A represents the relative surface area and m the slope of the isotherm. Here, 'm' was 287 calculated via 'm = $\frac{y^2 - y_1}{x^2 - x_1}$ over the surface pressure range of 10-30mN/m, whereby 'y' and 'x' values 288 characterise surface pressure and area values, respectively [20].

289	3.	Results	&	Discussion

291 3.1 Chemical Analysis of Smoke Vapour and Potential Impact on the Body

292

Cigarette smoke contains thousands of chemical components, some of which are naturally occurring within the tobacco plant whilst others are added as additives during manufacture [24]. The nicotine component of the Marlboro Gold cigarette vapour tested herein was 0.043mg/ml \pm 0.009, the quantity of this compound corresponded to that stated by the manufacturing company. The 1st generation e-cigarette vapour produced a mean nicotine concentration of 0.048 mg/ml \pm 0.006, with the 3rd generation e-cigarette vapour producing a value of 0.035 mg/ml \pm 0.003. The data demonstrated good reproducibility through all cigarette types.

300

301 3.2 Gas Chromatography / Mass Spectroscopy Data

302

GC-MS analysis of the cigarette / e-cigarette vapour component composition is illustrated in Figure 3aand Figure 3b.




Figure 3. The principal components of cigarette vapour as determined by GC-MS. (a) cigarette vapour; (b) ecigarette vapour.

308

The analysis confirms that nicotine and the related minor alkaloid components are the most abundant compounds within the cigarette vapour. In addition, the vapour sample demonstrated a proportion of additive compounds. The compounds representing the 'other' section included amines, and smoke related vapours, such as toluene. With reference to the composition data relating to both the 1st and 3rd generation e- cigarette vapour, it is apparent that nicotine is present, but it is not the major component. The addition of propylene glycol and glycerin to the e-cigarette formulations accounts for a large proportion of the compounds present (i.e. >75% of the total composition) [18]. Toluene and xylene were detected within the cigarette vapour extract by the GC-MS element of this investigation. Exposure to the former can be detrimental to white blood cell function and this can in turn pre-dispose to respiratory tract infections [25]. Furthermore, exposure to xylene at levels greater than 200 ppm can irritate the lungs leading to acute shortness of breath accompanied by chest pain [26].

321 In terms of the e-cigarette vapour, this route of nicotine administration to the body may be 322 considered less harmful than the more natural, counterpart products. With regard to this system of 323 nicotine delivery, during 2011 Trehy and co-workers documented that the composition of refill 324 products varies considerably as a result it is difficult to fully evaluate the hazards related to 325 electronic cigarette usage [27]. The content of the aerosol generated from e-cigarette is highly 326 variable, not only among different products but also within different samples of the same e-liquids 327 [16, 17, 27, 28, 29 & 30]. Therefore, we suggest that further work is required to better understand 328 the impact of the spectrum of e-cigarette products may have on pulmonary function.


329 During this work we have carefully replicated the main stages of cigarette / e-cigarette use via 330 reference to a typical puffing regimen [19] and applied the acquired vapour to a test zone housing a 331 model pulmonary surfactant system representative of typical in vivo lipid fractions under 332 physiologically relevant conditions [11]. The accepted mechanism of action for pulmonary 333 surfactant, and model mixtures thereof, revolves around the unsaturated lipid fraction (e.g. POPG) 334 forming a fluid-like liquid-expanded matrix to separate phases rich in condensed saturated lipids 335 (e.g. DPPC) [1 & 31]. The delicate coexistence between each phase at the alveolar air-liquid 336 interface is essential for effective surfactant function (i.e. to regulate surface viscosity and lower 337 surface tension) [11, 14 & 31]. Clearly, any disruption to the synergy between the liquid-expanded 338 and liquid-condensed phases forming the surfactant film can have a detrimental impact on gross 339 lung function [1 & 21]. Within the laboratory setting, deviation in recorded Langmuir pressure-area 340 isotherms and / or isocycles provides direct evidence of changes to overall surfactant performance.

- 341
- 342
- 343
- 344
- 345
- 346

347 3.3 Langmuir Pressure – Area Isotherms



Langmuir pressure-area isotherms were acquired for the simulated pulmonary surfactant systems 349 when exposed to either cigarette or e-cigarette vapour under conditions reflective of the (deep) 350 351 lung; relevant data are presented in Figures 4 and 5, respectively. All systems exhibit twodimensional phase changes over the course of compression; movement through the gaseous, 352 expanded and condensed phases is confirmed on gradient change from right to left. Here, the 353 354 compressibility parameter was considered with the slope of the trace used as a marker for the 355 compressibility of the two-dimensional film; where the steeper the slope, the harder it is to 356 compress the surfactant monolayer [32].



357

358

Figure 4. A Langmuir pressure-area isotherm detailing the response of a simulated pulmonary surfactant
 monolayer to cigarette vapour addition under physiologically relevant conditions, namely 37°C and elevated
 relative humidity. Averaged data of 5 replicates presented with standard error of the mean displayed.

362

363 On inspection of the data presented in Figure 4, it is clear that the administration of cigarette vapour 364 to the test zone did influence simulated pulmonary surfactant structure-function activity. Here, the 365 ability to attain low surface tension values at any given relative area is reduced and there is an 366 increase in the ease of compression under physiologically relevant conditions (i.e. the monolayer is 367 more compressible). 368 In the case of the model surfactant system studied herein, the highest surface pressure recorded in the absence of cigarette smoke was 41mN/m. This value was as a direct result of applying 10µl of 369 370 the surfactant spreading solution (1mg/ml) to the supporting aqueous subphase, which was deemed 371 appropriate to achieve smooth lipid phase transitions during compression and prevent solid phase 372 saturation at minimal trough areas. If a larger spreading solution volume were to be applied to the 373 aqueous subphase then the maximum surface pressure would rise (e.g. attain a value of 374 approximately 70mN/m). On application of cigarette vapour, the value of 41mN/m diminished to 375 32mN/m. Hence, the capacity to lower the surface tension at full monolayer compression was 376 reduced by 22%. In addition, exposure of cigarette vapour resulted in the monolayer exhibiting a 377 condensed character (i.e. being transposed to the left of the baseline plot). Comparable trends, as 378 those noted here, would be anticipated at higher surface pressure values (e.g. 70mN/m) [11].

A similar response was noted when 1st and 3rd generation e-cigarette vapour was delivered to the 379 380 test zone. Once again the baseline plot for our system exhibited a maximum surface pressure of 381 41mN/m (i.e. due to the application of 10μ l of material) with reduction in the term evident on exposure to 1st generation and 3rd generation e-cigarette vapour; namely 32mN/m and 36mN/m, 382 respectively. It is interesting to note that on delivery of the 1st generation e-cigarette vapour an 383 384 identical reduction in the surface pressure term of 22% was noted. This deviation was less in the case of the 3rd generation product, namely a 12% reduction. The presence of e-cigarette vapour led 385 386 to a reduction in the maximum surface pressure from the baseline data, this finding is statistically 387 significant due to the absence of overlap in the presented standard error of the mean bars. 388 Furthermore, as previously noted exposure to e-cigarette vapour caused a clear decrease in surface 389 pressure at any corresponding area. 390






Figure 5. Langmuir pressure-area isotherm data outlining the response of a simulated pulmonary surfactant
 monolayer to e-cigarette vapour addition under physiologically relevant conditions, namely 37°C and elevated
 relative humidity. Averaged data of 5 replicates presented with standard error of the mean displayed.

396 Similar responses to those outlined above have been noted within the literature [11]. All data 397 presented within this piece are reflected of the *in vivo* situation where smoke vapour would interact 398 with pulmonary surfactant via a 'top-down' approach. In this instance, the hydrocarbon chains of 399 the phospholipid molecules were primarily exposed to those chemicals within the smoke aliquots. 400 Therefore, this work considers real-world interfacial interactions that can potentially compromise 401 the biological function of the lung. Furthermore, in support of our findings Kannisto and Yhteiskoulu 402 reported functional changes in the lipid fraction of pulmonary surfactant as a result of phospholipid 403 degradation and / or the penetration of nicotine molecules into the two-dimensional film during 404 their 2006 study [33].


405

406 3.3.1 Langmuir Isotherm Compressibility Analysis

407

In order to quantify the impact of cigarette / e-cigarette vapour had on simulated pulmonary surfactant compressibility Equation 1 was applied. Here, the slope of the Langmuir pressure-area isotherm was considered along the liquid-expanded to liquid-condensed transition. That is to say between the surface pressures of 10mN/m to 30mN/m at the specific relative trough areas of 40%, 50% and 70%. Compressibility data for each system is presented in Figure 6.





415 **Figure 6.** The compressibility of simulated pulmonary surfactant monolayers at pre-defined relative trough 416 areas in the absence and presence of cigarette / e-cigarette vapour. In all cases of single monolayer 417 compression (i.e. Langmuir isotherms), the delivery of such vapour to the test zone increased the 418 compressibility term.

419

420 On exposure to cigarette / e-cigarette vapour, the compressibility term increased in all cases. 421 Greater compressibility values indicate that the surfactant film becomes less rigid in nature and 422 more elastic (i.e. easier to compress when compared to the baseline). This effect is more 423 pronounced in the case of exposure to cigarette vapour. The impact on monolayer compressibility is 424 limited in the case of the 3rd generation e-cigarette.

Although the use of Langmuir isotherms is not representative of the human breathing cycle, which is dynamic in nature, we believe that the information obtained from this largely static system can provide insight into the way in which environmental toxins (e.g. cigarette / e-cigarette vapour) can influence individual molecular species that are in the main fully exposed at the alveolar air-liquid interface (i.e. when in the gaseous phase). Here, we liken this situation to a lone soldier under attack from an opposing force.

- 431
- 432
- 433
- 434


435 In all cases, exposure to cigarette / e-cigarette vapour resulted in the simulated pulmonary 436 surfactant monolayer exhibiting a condensed character. Consequently, the ability to reduce the 437 surface tension term was impaired across all relative trough areas during compression to the centre 438 of the compartment. In addition, there was an apparent increase in monolayer compressibility. 439 Clearly, exposure to vapour from all platforms had a detrimental impact on simulated pulmonary 440 surfactant performance with exposure to cigarette vapour and the 1st generation e-cigarette vapour 441 being the most significant. There are a number of reasons to explain the notable trend in the data 442 sets presented herein. A previously reported aspect involves a reduction in phospholipid content 443 within the surfactant film due to exposure to the chemical constituents of smoke vapour (e.g. free 444 radicals and oxidising agents) [11]. Importantly, we believe that a key mechanism of surfactant film 445 degradation lies in the ability of neutral nicotine molecules within smoke vapour to penetrate in-446 between the relatively exposed phospholipid polar head groups of the surfactant film. On 447 inhalation, nicotine in the unionised form is able to enter the body and can readily pass across 448 membrane structures as opposed to protonated nicotine [34]. As such, the tobacco industry 449 typically designs cigarettes to have a large proportion of unprotnonated nicotine for inhalation to 450 enhance lung deposition and delivery to the brain [35]. Consequently, when the surfactant film is in 451 the uncompressed state (i.e. with the individual surfactant molecules decidedly exposed for 452 interaction) neutral nicotine could potentially weaken intermolecular van der Waals forces and 453 cause structural destabilisation, which will ultimately increase the compressibility of the material 454 (i.e. cause it to be less rigid) [33].

455 Tobacco-specific nitrosamines can also have a detrimental impact on the mechanical properties of 456 surfactant monolayers (i.e. by degrading individual phospholipid molecules) [36]. For example, NNN 457 and NNK are primary carcinogenic tobacco-specific nitrosamines that are present in cigarette smoke 458 [37]. Upon interaction with a surfactant film, these agents enhance phospholipid hydrolysis and 459 subsequently reduce content within the alveolar space; an accompanied increase in 460 lysophospholipid is also noted [28]. Within the body, lysophospholipids are formed as a result of 461 phospholipase A2 stereoselective hydrolysis of the ester linkage of phospholipids to release fatty 462 acids and lysophospholipids [38]. The lysophospholipids produced also have a direct detergent-like 463 effect on the surfactant leading to impaired surface activity and consequently lead to a reduction in 464 rigidity across the two-dimensional plane [21].

465

466

Langmuir pressure-area isocycles were also recorded for each system under conditions reflective of the *in vivo* scenario such that the impact of smoke vapour on surfactant dynamics could be assessed; representative plots are presented in Figures 7, 8 and 9. Again, the presence of cigarette / ecigarette vapour within the test zone did impact simulated pulmonary surfactant function. In each case, the surfactant film exhibits a condensed character and the ability to lower the surface tension at all stages throughout compression is weakened.



476 477

468

3.4 Langmuir Pressure – Area Isocycles

Figure 7. Langmuir pressure-area isocycle data relating to the response of a simulated pulmonary surfactant
monolayer to cigarette vapour addition under physiologically relevant conditions, namely 37°C and elevated
relative humidity. Averaged data of 3 replicates presented with standard error of the mean displayed. Where,
each replicate consists of 10 compression-expansion cycles at a barrier speed of 100cm² / min.

482


With regard to the baseline systems (i.e. Langmuir isocycles in the absence of cigarette / e-cigarette vapour), the maximum recorded surface pressure was 36mN/m during this work on addition of 10µl spreading solution to the surface of the supporting aqueous subphase. This value is comparable to that previously observed for the Langmuir isotherm element of this study, with the slight reduction due to monolayer pre-conditioning (i.e. the execution of 4 compression – expansion cycles) to attain the equilibrium state.

- 489
- 490

491 Following exposure to cigarette vapour, the ability of the simulated pulmonary surfactant film to 492 reduce the surface tension term was impaired at all relative trough areas. The result may be 493 ascribed to a reduction in the total phospholipid / lipid content of the surfactant film [14 & 21]. 494 Moreover, if the gradient of the trace between the surface pressures of 10mN/m and 30mN/m is 495 considered, it is apparent that the surfactant film exposed to the cigarette vapour is less 496 compressible (i.e. harder to compress) when compared to the baseline isotherm. Thus, the data 497 indicate that exposure to cigarette vapour increases the work required to compress the simulated 498 pulmonary surfactant monolayer to the minimum trough area.

499 On expansion, the simulated pulmonary surfactant monolayer exposed to cigarette smoke followed a similar pattern to that of the baseline system. The result confirms that the material is able to 500 501 respread after exposure to smoke vapour. Furthermore, the apparent hysteresis between 502 compression and expansion cycles was constant. Interestingly, the difference in collapse pressure 503 before and after exposure to smoke was less significant compared to the single compression 504 isotherm presented in Figure 4; in this case only an 11% reduction was calculated for the term. We 505 attribute this result to a 'protective mechanism' on dynamic monolayer compression - expansion 506 cycling and suggest that the lipid peroxidation effects contribute to the chemical degradation of the 507 POPG molecule that is primarily responsible for maintaining the fluidity of the surfactant film.

508 Following exposure to e-cigarette vapour, the simulated pulmonary surfactant monolayers were not 509 significantly degraded and once again displayed condensed character as illustrated in Figures 8 and 510 9. Here, the ability to lower the surface tension term at all relative areas was reduced, as previously 511 noted in the case of the cigarette vapour addition. In contrast to the previous system, the data 512 confirm that the maximum surface pressure of 36mN/m is attained subsequent to e-cigarette 513 vapour exposure. Thus, there is limited impact on attaining the maximum surface pressure value.



516 **Figure 8.** Langmuir pressure-area isocycle data relating to the response of a simulated pulmonary surfactant 517 monolayer to 1st generation e-cigarette vapour addition under physiologically relevant conditions, namely 37°C

518 and elevated relative humidity. Averaged data of 3 replicates presented with standard error of the mean 519 displayed. Where, each replicate consists of 10 compression-expansion cycles at a barrier speed of 100cm² / 520 min.

521




Figure 9. Langmuir pressure-area isocycle data relating to the response of a simulated pulmonary surfactant
 monolayer to 3rd generation e-cigarette vapour addition under physiologically relevant conditions, namely 37°C
 and elevated relative humidity. Averaged data of 3 replicates presented with standard error of the mean
 displayed.

527 We attribute the apparent deviation between each Langmuir isocycle to both the loss / degradation of amphiphilic material at the air-liquid interface and the penetration of nicotine molecules between 528 529 the polar head groups of the constituent molecules [11 & 33]. The reduction in the surface pressure 530 is more pronounced upon exposure to the vapour generated from the 1st generation e-cigarette. Here, there is a clear translocation to the left within the plot when compared with baseline starting 531 532 from approximately 1mN/m up towards 28mN/m. Such deviation is not as apparent shift in the case of exposure to 3rd generation e-cigarette vapour. In the case of exposure to both 1st and 3rd 533 generation e-cigarette vapour exposure, the hysteresis between the expansion and compression 534 phases are of similar sizes to that presented within the baseline. 535

- 536
- 537 538

3.4.1 Langmuir Isocycle Compressibility Analysis

In a similar fashion to that previously described, consideration was given to the quantitative determination of the influence cigarette / e-cigarette vapour had on simulated pulmonary surfactant compressibility during active cycling; once again Equation 1 was applied. Here, the slope of the Langmuir pressure-area isocycle was considered along the liquid-expanded to liquid-condensed transition. That is to say, between the surface pressures of 10mN/m to 30mN/m at the specific relative trough areas of 40%, 50% and 70%. Compressibility data for each system is presented in Figure 10.




Figure 10. The compressibility of simulated pulmonary surfactant monolayers at pre-defined relative trough areas in the absence and presence of cigarette / e-cigarette vapour. In all cases of repeated monolayer compression-expansion (i.e. Langmuir isocycles), the delivery of such vapour to the test zone decreased the compressibility term.

551 Following exposure to cigarette / e-cigarette vapour, the compressibility term decreased. Lower 552 compressibility values indicate that the surfactant film became more rigid in character and thus 553 harder to compress when compared to the baseline. This effect was more pronounced in the case of 554 the 1st generation e-cigarette vapour, demonstrating a potentially greater adverse effect on 555 pulmonary surfactant activity. As per previously noted, the influence on monolayer compressibility 556 is minimal in the case of the 3rd generation e-cigarette; this point supports the usefulness of the 557 more recently developed electronic products (e.g. PREPs) to support harm reduction within the 558 population.

559 The use of Langmuir isocycles closely represents the *in vivo* scenario. In this case, the collection of 560 amphiphilic molecules experience a two-dimensional lateral force on trough barrier movement to 561 the centre of the compartment with the phospholipid head groups less accessible to environmental 562 toxins and hence may be described as 'protected'. During surfactant compression-expansion cycles, 563 the fluid phase associated with surface active material is rapidly exchanged between the monolayer 564 interface and the adjoining surface associated reservoir [14 & 31]. As the monolayer is compressed, 565 the increase in surface pressure directs a fraction of the unsaturated lipid component (i.e. POPG) 566 away from the interfacial zone to desorb into the surface-associated, multilayer reservoir [39]. On 567 expansion, these fluid phase components stored in the surface associated reservoir support the 568 readsorption of the lipid fraction back to the interfacial zone [31]. The presence of cigarette / e-569 cigarette vapour within the vicinity of a surfactant film inhibits such exchange mechanisms and 570 therefore alters the proportion of phospholipids within the two-dimensional monolayer [14]. As 571 such, the mechanical properties of the monolayer film are adversely affected (i.e. there is an 572 apparent increase in film rigidity) which ultimately impairs the surface tension lowering capacity of 573 the material [11].

574 This point is confirmed by the apparent decrease in monolayer compressibility and impairment in 575 the ability to reduce the surface tension term at all relative trough areas. A number of mechanisms 576 have been proposed to explain such findings and include for example the presence of oxygen 577 derived free radicals within cigarette vapour that are capable of reducing the amount of unsaturated lipids (i.e. POPG) within the two-dimensional ensemble via peroxidation of double carbon-carbon 578 579 bonds within the acyl chains [40]. The net result is the presentation of a rigid interface that is high in 580 solid phase domains. This type of reaction involves the oxidative degradation of the amphiphilic species by free radicals contained within cigarette vapour [41]. 581

582

The oxidation of unsaturated components within a lipid monolayer (i.e. the exposed acyl chain groups of the ensemble) is anticipated due to the availability of multiple double bonds accompanied by methylene bridges that possess especially reactive hydrogen atoms [42]. Naturally, a reduction in the liquid phase within a rigid monolayer leads to poor respread profile on expansion and reduced surfactant coverage at the air-liquid interface [43].

589 The data presented within this study clearly demonstrate that exposure to cigarette / e-cigarette 590 vapour has a detrimental impact on the activity of a simulated pulmonary surfactant film. The 591 amphiphilic material forming the surfactant monolayer is central to the regulation of the surface 592 tension parameter at the alveolar air-liquid interface [14 & 21]. As such, if we take the findings 593 presented within this study and extrapolate to the in vivo scenario, an increase in the work of 594 breathing would be anticipated. The net effect of this would be impaired lung function, which could 595 manifest as compromised gaseous exchange within the (deep) lung, potential collapse or incomplete 596 inflation of the lung structure itself, hypoxia, oedema and quite possibly pulmonary hypertension [41 597 & 44]. Furthermore, due to such deviation from the healthy state, scope exists for longstanding 598 conditions to develop including for example chronic obstructive pulmonary disease (COPD) along 599 with interstitial lung disease. Overall, impairment to lung mechanics would be expected [44]. 600 Indeed, previous work has confirmed significant reductions in phospholipid concentrations in the 601 bronchoalveolar lavage fluid obtained from those who smoke cigarettes and experience COPD [45 & 602 46]. Thus, the lung-specific adverse effects associated with cigarette smoking can reduce the quality 603 of life of the individual and increase the likelihood of premature death.

604 Over the course of recent years, e-cigarettes have become increasingly popular within developed 605 countries because of the possibility of delivering nicotine to the body in a clean format whilst 606 concurrently satisfying behavioural triggers [17, 29 & 47]. In relation to this point, during 2014 Safari 607 and co-workers documented the fact that e-cigarettes can reliably deliver nicotine to the lung whilst 608 limiting the exposure to tobacco specific toxins when compared with traditional cigarettes and the 609 use of hence it is a healthier alternative from a public health perspective [48]. However, potential 610 drawbacks to the wide spread uptake of e-cigarettes involve the lack of quality control and manufacturing regulations currently in place. For instance, such regulations do not fully cover 611 612 aspects comprising raw material inclusion, purification stages and batch-to-batch consistency of e-613 liquid refills; all of which can impact upon the vapour profile from the respective products [17, 18, 48] & 49]. Clearly, these elements require further detailed investigation. 614

616 Although not reported here, some commercially available e-liquid and cartridge refills do contain 617 chemicals that may pose potential health risks to the individual; interestingly these agents have also 618 been detected within tobacco smoke vapour [16, 17, 18, 27, 47 & 48]. For example, the cytotoxic 619 and carcinogenic substances including formaldehyde, NNN, NNK and acrolein have been identified 620 within e-cigarette vapour; all may have deleterious effects on the human body [16, 17 & 48]. 621 Although the concentration of such substances is much lower than in traditional cigarette vapour, 622 alteration of pulmonary surfactant activity is possible at the alveolar air-liquid interface and this can 623 in turn initiate the presentation and development of the lung related complications / disease states 624 listed above [1, 11 & 50].

625

626 **4. Conclusion**

627

This study has demonstrated that exposure to cigarette / e-cigarette vapour does modify the 628 629 structure-function activity of simulated pulmonary surfactant monolayers under physiologically 630 relevant conditions. The results offer insight into the potential effects such (environmental) toxins 631 can have on the human lung. With reference to the dynamic system investigated herein, the 632 capacity to reduce the surface tension term was impaired throughout and the compressibility of the surfactant film was reduced in all cases. The findings were ascribed to the chemical interactions 633 634 taking place between pulmonary surfactant-specific components and the smoke vapour delivered to the test zone. We propose key mechanisms of interaction include: a) nicotine insertion into the two-635 636 dimensional phospholipid ensemble, b) lipid peroxidation of the amphiphilic acyl chains and c) 637 hydrolysis of the phospholipid chains via tobacco-specific nitrosamine association.

638 Detrimental interactions such as these can cause molecular destabilisation and inhibit phospholipid 639 exchange with the surface associated reservoir system. Correspondingly, a reduction in lung 640 compliance can lead to the development of a range of lung specific complications including 641 pulmonary oedema and COPD; the latter condition is frequently noted with the chronic smoker. 642 Undoubtedly, further work is required to gain greater insight into the delicate interplay between 643 environmental toxins and the pulmonary space. Such investigation may now be readily conducted 644 via use of the lung biosimulator platform presented within this piece. Here, scope exists to consider 645 the influence of a wide range of environmental toxins have on lung function, including for example 646 petrol and diesel fumes. This device also holds potential to quantitatively probe the interaction 647 between respirable therapeutic formulations and the deep lung (e.g. in pharmaceutical dissolution 648 testing).

C 4 0	-		
649	5.	Acknowl	edgements

The team would like to thank LJMU for funding this research effort. Special thanks go to Mr PaulBurgess, Mr Phil Salmon and Mr Geoffrey Henshaw for technical support throughout.

653

654 6. References

655

Scott J. The Pulmonary Surfactant: Impact of Tobacco Smoke and Related Compounds on
 Surfactant and Lung Development. *Tob Induced Dis.* 2004, 2(1), 1.

- Nahak, P.; Nag, K.; Hillier, A.; Devraj, R.; Thompson, D.; Manna, K.; Makino, K.; Ohshima, H.;
 Nakahara, H.; Shibata, O.; Panda, AK. Effect of Serum, Cholesterol and Low Density
 Lipoprotein on the Functionality and Structure of Lung Surfactant Films. *Journal of Oleo Science*. 2014; 63(12), 1333-1349.
- Keating, E.; Rahman, L.; Francis, J.; Petersen, A.; Possmayer, F.; Veldhuizen, R.; Petersen, NO.
 Effect of Cholesterol on the Biophysical and Physiological Properties of a Clinical Pulmonary
 Surfactant. *Biophysical Journal*. 2007, 93(4), 1391-1401.
- 4. Davies, M.; Brindley, A.; Chen, X.; Doughty, S.; Marlow, M.; Roberts, C. A quantitative
 assessment of inhaled drug particle–pulmonary surfactant interaction by atomic force
 microscopy. *Colloids and Surfaces B: Biointerfaces*. 2009, 73(1), 97-102.
- 668 5. Ward, J.; Ward, J.; Leach, RM. The Respiratory System at a Glance. 2011. Hoboken: John
 669 Wiley & Sons, Singapore.
- 670 6. Eastwood, P. Statistics on Smoking England. Health and Social Care Information Centre.
 671 2012.
- Davies, M.J.; Kerry, T.; Seton, L.; Murphy, M.; Gibbons, P.; Khoo, J.; Naderi, M. The crystal
 engineering of salbutamol sulphate via simulated pulmonary surfactant monolayers. *International Journal of Pharmaceutics*. 2013, 446(1-2), 34-45.
- 8. Zasadzinski, J.; Ding, J.; Warriner, H.; Bringezu, F.; Waring, A. The physics and physiology of
 lung surfactants. *Current Opinion in Colloid & Interface Science*. 2001, 6(5-6), 506-513.
- 9. Parra, E.; Pérez-Gil, J. Composition, structure and mechanical properties define performance
 of pulmonary surfactant membranes and films. *Chemistry and Physics of Lipids*. 2015, 185,
 153-175.
- 10. Lotze A. Survanta[®] Pre-ecmo Trial: Multicenter evaluation of Survanta[®] in treatment of term
 infants with severe respiratory failure. 1341. *Pediatr Res.* **1996**, 39, 226-226.

- 682 11. Bringezu, F.; Pinkerton, K.; Zasadzinski, J. Environmental Tobacco Smoke Effects on the
 683 Primary Lipids of Lung Surfactant. *Langmuir*. 2003, 19(7), 2900-2907.
- 12. Davies, M.J.; Seton, L.; Tiernan, N.; Murphy, M.F.; & Gibbons, P. Towards crystal
 engineering via simulated pulmonary surfactant monolayers to optimise inhaled drug
 delivery. *International Journal of Pharmaceutics*. 2011, 421, 1–11.
- 587 13. Davies, M.J. International patent application: WO2014199178. Title: Device and method for
 588 simulating pulmonary environments. **2014**.
- 14. Stenger, P.; Alonso, C.; Zasadzinski, J.; Waring, A.; Jung, C.; Pinkerton, K. Environmental
 tobacco smoke effects on lung surfactant film organization. *Biochimica et Biophysica Acta*(*BBA*) *Biomembranes*. 2009, 1788(2), 358-370.
- 692 15. Brown, J.; West, R.; Beard, E.; Michie, S.; Shahab, L.; McNeill, A. Prevalence and
 693 characteristics of e-cigarette users in Great Britain: Findings from a general population
 694 survey of smokers. *Addict Behav.* 2014, 39(5), 1120–1125.
- 695 16. Uchiyama, S.; Ohta, K.; Inaba, Y.; Kunugita, N. Determination of carbonyl compounds
 696 generated from the E-cigarette using coupled silica cartridges impregnated with
 697 hydroquinone and 2,4-dinitrophenylhydrazine, followed by high-performance liquid
 698 chromatography. *Anal Sci.* 2013, 29(12), 1219-1222.
- Goniewicz, M.L.; Knysak, J.; Gawron, M.; Kosmider, L.; Sobczak, A.; Kurek, J.; Prokopowicz,
 A.; Jablonska-Czapla, M.; Rosik-Dulewska, C.; Havel, C.; Jacob III, P.; Benowitz, N. Levels of
 selected carcinogens and toxicants in vapour from electronic cigarettes. *Tob Control.* 2014,
 23(2), 133-139.
- 18. Tayyarah, R.; Long, G. Comparison of select analytes in aerosol from e-cigarettes with smoke
 from conventional cigarettes and with ambient air. *Regulatory Toxicology and Pharmacology*. 2014, 70(3), 704-710.
- 19. Health Canada. Determination of "tar", nicotine and carbon monoxide in mainstream
 tobacco smoke. Tobacco Control. **1999**.
- Shah, A.R.; Banerjee, R. Effect of D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)
 on surfactant monolayers. *Colloids and Surfaces B*. **2011**, 85, 116-124.
- 21. Subramaniam, S. Biochemical and Biophysical Characterization of Pulmonary Surfactant in
 Rats Exposed Chronically to Cigarette Smoke. *Fundamental and Applied Toxicology*. 1995,
 27(1), 63-69.
- 22. Khattari, Z.; Langer, U.; Aliaskarisohi, S.; Ray, A.; Fischer, M. Effects of soluble surfactants on
 the Langmuir monolayers compressibility: A comparative study using interfacial isotherms
 and fluorescence microscopy. *Materials Science and Engineering C.* 2011, 31, 1711–1715.

- 716 23. Behroozi, F. Theory of Elasticity in Two Dimensions and Its Application to Langmuir–Blodgett
 717 Films. *Langmuir.* 1996, 12 (9), 2289–2291.
- 718 24. Chan-Yeung, M.; Dimich-Ward, H. Respiratory health effects of exposure to environmental
 719 tobacco smoke. *Respirology*. 2003, 8(2), 131-139.
- 25. Akbaş, E.; Derici, E.; Söylemez, F.; Kanik, A.; Polat, F. An investigation of effects of toluene
 and cigarette smoking on some blood parameters and lymphocyte life span. *Cell Biol Toxicol*.
 2004, 20(1), 33-40.
- 723 26. Kandyala, R.; Raghavendra, S; Rajasekharan, S. Xylene: An overview of its health hazards and
 724 preventive measures. *Journal of Oral and Maxillofacial Pathology*. 2010, 14(1), p.1.
- 725 27. Trehy, M.L.; Ye, W.; Hadwiger, M.E.; Moore, T.W.; Allgire, J.F.; Woodruff, J.T.; Ahadi, S.S.;
 726 Black, J.C.; Westenberger, B.J. Analysis of electronic cigarette cartridges, refill solutions, and
 727 smoke for icotine and nicotine related impurities. *Liq Chrom Relat Tech.* 2011, 34(14), 1442728 1458.
- Vijayaraj, P.; Sivaprakasam, C.; Varthini, L.; Sarkar, M.; Nachiappan, V. In vitro exposure of
 tobacco specific nitrosamines decreases the rat lung phospholipids by enhanced
 phospholipase A2 activity. *Toxicology in Vitro*. 2014, 28(6), 1097-1105.
- 732 29. Farsalinos, E. K.; Romagna, G.; Allifranchini, E.; Ripamonti, E.; Bocchietto, E.; Todeschi, S.;
 733 Tsiapras, D.; Kyrzopoulos, S.; Voudris, V. Comparison of the Cytotoxic Potential of Cigarette
 734 Smoke and Electronic Cigarette Vapour Extract on Cultured Myocardial Cells. *Int. J. Environ.*735 *Res. Public Health.* 2013, 10(10), 5146-5162.
- 30. Schripp, T.; Markewitz, D.; Uhde, E.; Salthammer, T. Does e-cigarette consumption cause
 passive vaping? *Indoor Air*, **2012**, 23, 25-31.
- 31. Ding, J.; Takamoto, D.; von Nahmen, A.; Lipp, M.; Lee, K.; Waring, A.; Zasadzinski, J.A. Effects
 of Lung Surfactant Proteins, SP-B and SP-C, and Palmitic Acid on Monolayer Stability. *Biophysical Journal.* 2001, 80(5), 2262-2272.
- 32. Lyklema, J. Fundamentals of Interface and Colloid Science, Vol. III. 2000. Academic Press,
 London.
- 743 33. Kanisto, K.; Yhteiskoulu, H. Effects of Nicotine on a Primary Lipid of Lung Surfactant: Testing
 744 the Stability and Efficiency Using Subphases of Different Ion Strengths and pH. 2006.
- 745 34. Mayer, B. Nicotine the Basics. A Scientist's View about Nicotine and Tobacco. **2016**.
- 746 35. Rockville, M.D. How tobacco smoke causes disease. U.S. Dept. of Health and Human
 747 Services, Public Health Service, Office of the Surgeon General. 2010.

- 36. Wang, G.; Cheng, X.; Li, X.; Liu, Y.; Wang, X.; Shi, X.; Wang, Z.Y.; Guo, Y.Q.; Wen, Z.S.; Huang,
 Y.C.; Zhou, G.B. Tobacco smoke induces production of chemokine CCL20 to promote lung
 cancer. *Cancer Letters*. 2015, 363(1), 60-70.
- 37. Hecht, S.; Hoffmann, D. Tobacco-specific nitrosamines, an important group of carcinogens in
 tobacco and tobacco smoke. *Carcinogenesis*. **1988**, 9(6), 875-884.
- 38. Rodríguez-Capote, K.; Manzanares, D.; Haines, T.; Possmayer, F. Reactive Oxygen Species
 Inactivation of Surfactant Involves Structural and Functional Alterations to Surfactant
 Proteins SP-B and SP-C. *Biophysical Journal*. 2006, 90(8), 2808-2821.
- 39. Von Nahmen, A.; Schenk, M.; Sieber, M.; Amrein, M. The structure of a model pulmonary
 surfactant as revealed by scanning force microscopy. *Biophysical Journal*. **1997**, 72(1), 463469.
- 40. Soto-Arriaza, M.; Sotomayor, C.; Lissi, E. Relationship between lipid peroxidation and rigidity
 in L-α-phosphatidylcholine-DPPC vesicles. *Journal of Colloid and Interface Science*. 2008,
 323(1), 70-74.
- 762 41. Notter, R. Lung Surfactants. **2000**. New York, Marcel Dekker.
- 42. Anand, U.; Agarwal, R.; Anand, C. Pulmonary Lipid Peroxidation in Cigarette Smokers and
 Lung Cancer Patients. *Chest.* **1992**, 101(1), 290.
- 43. Alonso, C.; Alig, T.; Yoon, J.; Bringezu, F.; Warriner, H.; Zasadzinski, J. More Than a
 Monolayer: Relating Lung Surfactant Structure and Mechanics to Composition. *Biophysical Journal.* 2004, 87(6), 4188-4202.
- 44. Akella, A.; Deshpande, B.S. Pulmonary Surfactants and their Role in Pathophysiology of Lung
 Disorders. *Indian Journal of Experimental Biology*. 2013, 51, 5-22.
- 45. Lusuardi, M.; Capelli, A.; Carli, S.; Tacconi, M.; Salmona, M.; Donner, C. Role of Surfactant in
 Chronic Obstructive Pulmonary Disease: Therapeutic Implications. *Respiration*. 1992, 59(1),
 28-32.
- 46. Zetterberg, G.; Curstedt, T.; Eklund, A. A possible alteration of surfactant in bronchoalveolar lavage fluid from healthy smokers compared to non-smokers and patients with
 sarcoidosis. Sarcoidosis. 1995, 12, 46-50.
- 47. Kosmider, L.; Sobczak, A.; Fik, M.; Knysak, J.; Zaciera, M.; Kurek, J.; Goniewicz, M.L. Carbonyl
 Compounds in Electronic Cigarette Vapors Effects of Nicotine Solvent and Battery Output
 Voltage. *Nicotine Tob Research*. 2014.
- 779
- 780

- 48. Saffari, A.; Daher, N.; Ruprecht, A.; De Marco. C.; Pozzi, P.; Boffi, R.; Hamad, S.H.; Shafer,
 M.M.; Schauer, J.J.; Westerdahl, D.; Sioutas, C. Particulate metals and organic compounds
 from electronic and tobacco-containing cigarettes: comparison of emission rates and
 second-hand exposure. *Environ Sci Process Impacts.* 2014, 16(10), 2259-2267.
- 49. Hua, M.; Yip, H.; Talbot, P. Mining data on usage of electronic nicotine delivery systems
 (ENDS) from YouTube videos. *Tob Control.* 2011, 103-106.
- 50. Devendra, G.; Spragg, R.G. Lung surfactant in subacute pulmonary disease. *Respir Res.* 2002,
 3(1).